Уважаемые пользователи!

Данный сайт содержит информацию для людей с медицинским образованием и специалистов здравоохранения.
Входя на сайт, Вы подтверждаете свое согласие с Условиями использования и Политикой конфиденциальности.



Dear visitor!
This site contains medical information for healthcare professionals.
You can go further, if you agree with Terms and Conditions and Privacy Policy on this site.

Subclinical Cushing's syndrome due to unilateral or bilateral adrenal incidentalomas. Problems of diagnostic and indication to surgical treatment. Review of literature

Cover Page

Abstract


Today subclinical Cushing's syndrome is the most widespread variant of hormonal activity of incidentaloma's hormonal activity. This pathology is defined as a mild intensity autonomous cortisol hypersecretion, not causing specific clinical signs of hypercorticism, but detectable biochemically as derangements of the hypothalamic-pituitary-adrenal axis function. Some clinical symptomatology of metabolic syndrome, such as obesity, impaired carbohydrate metabolism and hypertension, are peculiar to subclinical hypercorticism more than to population. As a result all these symptomatology could lead to increasing cardiovascular risk. Till now there isn't a definite opinion about the need of surgical treatment of present pathology. But there is evidence, that after removing of incidentalomas clinical symptomatology of metabolic syndrome are improving. For understanding all possible risks, connected with subclinical hypercorticism, it's necessary to study the origins of their arising and present about the most adequate screening tests. 


Nikolay Sergeevich Kuznetsov

Endocrinology Research Centre, Moscow

Email: beltsevich@rambler.ru

Russian Federation MD, PhD, Head of the Surgeon department of the Endocrinology Research Centre

Olga Vladimirovna Tihonova

Endocrinology Research Centre, Moscow

Author for correspondence.
Email: helgatikhonova@yandex.ru

Russian Federation MD, resident endocrinologist in Endocrinology Research Centre

  • Nawar R. Adrenal incidentalomas - a continuing management dilemma. Endocr Relat Cancer. 2005;12(3):585-598. doi: 10.1677/erc.1.00951.
  • Kloos RT, Gross MD, Francis IR, et al. Incidentally discovered adrenal masses*. Endocr Rev. 1995;16(4):460-484. doi: 10.1210/edrv-16-4-460.
  • Reincke M. Subclinical ^siting's syndrome. Endocrinol Metab Clin North Am. 2000;29(1):43-56. doi: 10.1016/s0889-8529(05)70115-8.
  • Nieman LK. Approach to the patient with an adrenal inciden-taloma. J Clin Endocrinol Metab. 2010;95(9):4106-4113. doi: 10.1210/jc.2010-0457.
  • Terzolo M, Pia A, Reimondo G. Subclinical Сushing's syndrome: Definition and management. Clin Endocrinol. 2012;76(1):12-18. doi: 10.1111/j.1365-2265.2011.04253.x.
  • Zeiger MA, Siegelman SS, Hamrahian AH. Medical and surgical evaluation and treatment of adrenal incidentalomas. J Clin Endocrinol Metab. 2011;96(7):2004-2015. doi: 10.1210/jc.2011-0085.
  • Reincke M, Nieke J, Krestin GP, et al. Preclinical Сushing's syndrome in adrenal "incidentalomas": Comparison with adrenal Сushing's syndrome. J Clin Endocrinol Metab. 1992;75(3):826-832. doi: 10.1210/jcem.75.3.1517373.
  • Mantero F, Terzolo M, Arnaldi G, et al. A survey on adrenal incidentaloma in Italy. J Clin Endocrinol Metab. 2000;85(2): 637-644. doi: 10.1210/jcem.85.2.6372.
  • Beierwaltes WH, Sturman MF, Ryo U, et al. Imaging functional nodules of the adrenal glands with 131-I-19-iodocholesterol. J Nucl Med. 1974;15:246-251.
  • Bulow B, Jansson S, Juhlin C, et al. Adrenal incidentaloma -follow-up results from a swedish prospective study. Eur J Endocrinol. 2006;154(3):419-423. doi: 10.1530/eje.1.02110.
  • Barzon L, Fallo F, Sonino N, et al. Development of overt Cushing's syndrome in patients with adrenal incidentaloma. Eur J Endocrinol. 2002;146(1):61-66. doi: 10.1530/eje.0.1460061.
  • Mansmann G, Lau J, Balk E, et al. The clinically inapparent adrenal mass: Update in diagnosis and management. Endocr Rev. 2004;25(2):309-340. doi: 10.1210/er.2002-0031.
  • Cao C, Yang X, Li L, et al. Increased expression of cyp17 and cyp11b1 in subclinical Cushing's syndrome due to adrenal adenomas. Int J Urol. 2011;18(10):691-696. doi: 10.1111/j.1442-2042.2011.02836.x.
  • Mitsuhiro K, Masashi D, Takashi Y, et al. Epigenetic Controls of CYP11B2 and CYP11B1 Gene in Subclinical Cushing Syndrome Associated with Overproduction of Aldosterone. Endocrine Society's 96th Annual Meeting and Expo, June 21-24, 2014. Chicago; 2014.
  • Di Dalmazi G, Kisker C, Calebiro D, et al. Novel somatic mutations in the catalytic subunit of the protein kinase as a cause of adrenal Cushing's syndrome: A european multicentric study. J Clin Endocrinol Metab. 2014;99(10):E2093-E2100. doi: 10.1210/jc.2014-2152.
  • Vassilatou E, Vryonidou A, Michalopoulou S, et al. Hormonal activity of adrenal incidentalomas: Results from a long-term follow-up study. Clin Endocrinol. 2009;70(5):674-679. doi: 10.1111/j.1365-2265.2008.03492.x.
  • Terzolo M, Osella G, Ali A, et al. Subclinical Cushing's syndrome in adrenal incidentaloma. Clin Endocrinol. 1998;48(1):89-97. doi: 10.1046/j.1365-2265.1998.00357.x.
  • Terzolo M, Pia A, A№ A, et al. Adrenal incidentaloma: A new cause of the metabolic syndrome? J Clin Endocrinol Metab. 2002;87(3):998-1003. doi: 10.1210/jcem.87.3.8277.
  • Osella G, Terzolo M, Borretta G, et al. Endocrine evaluation of incidentally discovered adrenal masses (incidentalomas). J Clin Endocrinol Metab. 1994;79(6):1532-1539. doi: 10.1210/jcem.79.6.7989452.
  • Leibowitz G, Tsur A, Chayen SD, et al. Pre-clinical Cushing's syndrome: An unexpected frequent cause of poor glycaemic control in obese diabetic patients. Clin Endocrinol. 1996; 44(6):717-722. doi: 10.1046/j.1365-2265.1996.737558.x.
  • Chiodini I, Morelli V, Masserini B, et al. Bone mineral density, prevalence of vertebral fractures, and bone quality in patients with adrenal incidentalomas with and without subclinical hypercortisolism: An italian multicenter study. J Clin Endocrinol Metab. 2009;94(9):3207-3214. doi: 10.1210/jc.2009-0468.
  • Bohdanowicz-Pawlak A, Szymczak J, et al. Subclinical Cushing's syndrome in adrenal incidentalomas--possible metabolic consequences. Endokrynol Pol. 2013;64(3):186-191.
  • Chiodini I, Morelli V, Salcuni AS, et al. Beneficial metabolic effects of prompt surgical treatment in patients with an adrenal incidentaloma causing biochemical hypercortisolism. J Clin Endocrinol Metab. 2010;95(6):2736-2745. doi: 10.1210/jc.2009-2387.
  • Toniato A, Merante-Boschin I, Opocher G, et al. Surgical versus conservative management for subclinical Cushing's syndrome in adrenal incidentalomas: A prospective randomized study. Ann Surg. 2009;249(3):388-391. doi: 10.1097/SLA.0b013e31819a47d2.
  • Emral R, Uysal AR, Asik M, et al. Prevalence of subclinical Cushing's syndrome in 70 patients with adrenal incidentalo-ma: Clinical, biochemical and surgical outcomes. Endocr J. 2003;50(4):399-408. doi: 10.1507/endocrj.50.399.
  • Rossi R, Tauchmanova L, Luciano A, et al. Subclinical Cushing's syndrome in patients with adrenal incidentaloma: Clinical and biochemical features. J Clin Endocrinol Metab. 2000;85(4):1440-1448. doi: 10.1210/jcem.85.4.6515.
  • Midorikawa S, Sanada H, Hashimoto S, et al. The improvement of insulin resistance in patients with adrenal inci-dentaloma by surgical resection. Clin Endocrinol. 2001; 54(6):797-804. doi: 10.1046/j.1365-2265.2001.01274.x.
  • Bernini G, Moretti A, Iacconi P, et al. Anthropometric, haemo-dynamic, humoral and hormonal evaluation in patients with incidental adrenocortical adenomas before and after surgery. Eur J Endocrinol. 2003;148(2):213-219. doi: 10.1530/eje.0.1480213.
  • Karnieli E, Cohen P, Barzilai N, et al. Insulin resistance in Cushing's syndrome. Horm Metab Res. 2008;17(10): 518-521. doi: 10.1055/s-2007-1013593.
  • Stubbs M, York DA. Central glucocorticoid regulation of para-sympathetic drive to pancreatic -cells in the obese fa/fa rat. Int J Obes. 1991;15:547-553.
  • Tauchmanovа L, Rossi R, Biondi B, et al. Patients with sub-clinical Cushing's syndrome due to adrenal adenoma have increased cardiovascular risk. J Clin Endocrinol Metab. 2002;87(11):4872-4878. doi: 10.1210/jc.2001-011766.
  • Di Dalmazi G, Vicennati V, Rinaldi E, et al. Progressively increased patterns of subclinical cortisol hypersecretion in adrenal incidentalomas differently predict major metabolic and cardiovascular outcomes: A large cross-sectional study. Eur J Endocrinol. 2012;166(4):669-677. doi: 10.1530/eje-11-1039.
  • Liu Y, Mladinov D, Pietrusz JL, et al. Glucocorticoid response elements and 11-hydroxysteroid dehydrogenases in the regulation of endothelial nitric oxide synthase expression. Cardio-vasc Res. 2008;81(1):140-147. doi: 10.1093/cvr/cvn231.
  • Hamm LL, Hering-Smith KS. Pivotal role of the kidney in hypertension. Am J Med Sci. 2010;340(1):30-32. doi: 10.1097/MAJ.0b013e3181e590f0.
  • Rossi GP, Andreis PG, Colonna S, et al. Endothelin-1[1-31]: A novel autocrine-paracrine regulator of human adrenal cortex secretion and growth. J Clin Endocrinol Metab. 2002;87(1): 322-328. doi: 10.1210/jcem.87.1.8134.
  • Xiao D, Huang X, Bae S, et al. Cortisol-mediated potentiation of uterine artery contractility: Effect of pregnancy. Am J Physiol Heart Circ Physiol. 2002;283(1):H238-H246. doi: 10.1152/ajpheart.00842.2001.
  • Swiqtkowska-Stodulska R, Kaniuka-Jakubowska S, Wisni-ewski P, et al. Homocysteine and alpha-1 antitrypsin concentration in patients with subclinical hypercortisolemia. Adv Med Sci. 2012;57(2):302-307. doi: 10.2478/v10039-012-0032-8.
  • Morelli V, Palmieri S, Salcuni AS, et al. Bilateral and unilateral adrenal incidentalomas: Biochemical and clinical characteristics. Eur J Endocrinol. 2012;168(2):235-241. doi: 10.1530/eje-12-0777.
  • Morelli V, Eller-Vainicher C, Salcuni AS, et al. Risk of new vertebral fractures in patients with adrenal incidentaloma with and without subclinical hypercortisolism: A multicenter longitudinal study. J Bone Miner Res. 2011;26(8):1816-1821. doi: 10.1002/jbmr.398.
  • Chiodini I, Torlontano M, Carnevale V, et al. Bone loss rate in adrenal incidentalomas: A longitudinal study. J Clin Endocrinol Metab. 2001;86(11):5337-5341. doi: 10.1210/jcem.86.11.8022.
  • Zografos G, Perysinakis I, Vassilatou E. Subclinical Cushing's syndrome: Current concepts and trends. Hormones. 2014;13(3):323-337. doi: 10.14310/horm.2002.1506.
  • Birsen O, Akyuz M, Dural C, et al. A new risk stratification algorithm for the management of patients with adrenal incidentalomas. Surgery. 2014;156(4):959-966. doi: 10.1016/j.surg.2014.06.042.
  • Low G, Dhliwayo H, Lomas DJ. Adrenal neoplasms. Clin Radiol. 2012;67(10):988-1000. doi: 10.1016/j.crad.2012.02.005.
  • Lumachi F, Marchesi P, D, et al. CT and MR imaging of the adrenal glands in cortisol-secreting tumors. Anticancer Res. 2011;31:2923-2926.
  • Vassiliadi DA, Ntali G, Vicha E, et al. High prevalence of sub-clinical hypercortisolism in patients with bilateral adrenal incidentalomas: A challenge to management. Clin Endocrinol. 2011;74(4):438-444. doi: 10.1111/j.1365-2265.2010.03963.x.
  • Barzon L, Scaroni C, Sonino N, et al. Incidentally discovered adrenal tumors: Endocrine and scintigraphic correlates. J Clin Endocrinol Metab. 1998;83(1):55-62. doi: 10.1210/jcem.83.1.4501.
  • Tsagarakis S, Kokkoris P, Roboti C, et al. The low-dose dexa-methasone suppression test in patients with adrenal inciden-talomas: Comparisons with clinically euadrenal subjects and patients with Cushing's syndrome. Clin Endocrinol. 1998; 48(5):627-633. doi: 10.1046/j.1365-2265.1998.00464.x.
  • Nieman LK, Biller BMK, Findling JW, et al. The diagnosis of Cushing's syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008;93(5):1526-1540. doi: 10.1210/jc.2008-0125.
  • Stewart PM. Is subclinical Cushing's syndrome an entity or a statistical fallout from diagnostic testing? Consensus surrounding the diagnosis is required before optimal treatment can be defined. J Clin Endocrinol Metab. 2010;95(6):2618-2620. doi: 10.1210/jc.2010-0633.
  • Katabami T, Obi R, Shirai N, et al. Discrepancies in results of low- and high-dose dexamethasone suppression tests for diagnosing preclinical Cushing's syndrome. Endocr J. 2005;52(4):463-469. doi: 10.1507/endocrj.52.463.
  • Kasperlik-Zaluska AA, Roslonowska E, Slowinska-Srzed-nicka J, et al. Incidentally discovered adrenal mass (inciden-taloma): Investigation and management of 208 patients. Clin Endocrinol. 1997;46(1):29-37. doi: 10.1046/j.1365-2265.1997.d01-1751.x.
  • Reimondo G, Allasino B, Bovio S, et al. Pros and cons of dexamethasone suppression test for screening of subclinical Cushing's syndrome in patients with adrenal incidentalomas. J Endocrinol Invest. 2014;34(1):e1-e5. doi: 10.1007/bf03346701.
  • Grumbach MM. Management of the clinically inapparent adrenal mass ("incidentaloma"). Ann Intern Med. 2003;138(5): 424. doi: 10.7326/0003-4819-138-5-200303040-00013.
  • Zeiger M, Thompson G, Duh Q-Y, et al. American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons medical guidelines for the management of adrenal incidentalomas: Executive summary of recommendations. EndocrPract. 2009;15(5):450-453. doi: 10.4158/ep.15.5.450.
  • Ambrosi B, Peverelli S, Passini E, et al. Abnormalities of endocrine function in patients with clinically "silent" adrenal masses. Eur J Endocrinol. 1995;132(4):422-428. doi: 10.1530/eje.0.1320422.
  • Caplan RH. Subclinical hormone secretion by incidentally discovered adrenal masses. Arch Surg. 1994;129(3):291. doi: 10.1001/archsurg.1994.01420270067016.
  • Reincke M, Fassnacht M, Vath S, et al. Adrenal incidentalo-mas: a manifestation of the metabolic syndrome? Endocr Res. 1996;22:757-761.
  • Terzolo M, Bovio S, Reimondo G, et al. Subclinical Cushing's syndrome in adrenal incidentalomas. Endocrinol Metab Clin North Am. 2005;34(2):423-439. doi: 10.1016/j.ecl.2005.01.008.
  • Flecchla D, Mazza E, Carllni M, et al. Reduced serum levels of dehydroepiandrosterone sulphate in adrenal incidentalomas: A marker of adrenocortical tumour. Clin Endocrinol. 1995; 42(2):129-134. doi: 10.1111/j.1365-2265.1995.tb01852.x.
  • Masserini B, Morelli V, Bergamaschi S, et al. The limited role of midnight salivary cortisol levels in the diagnosis of subclinical hypercortisolism in patients with adrenal inciden-taloma. Eur J Endocrinol. 2008;160(1):87-92. doi: 10.1530/eje-08-0485.
  • Raff H. A physiologic approach to diagnosis of the Cushing's syndrome. Ann Intern Med. 2003;138(12):980. doi: 10.7326/0003-4819-138-12-200306170-00010.
  • Arnaldi G, Angeli A, Atkinson AB, et al. Diagnosis and complications of Cushing's syndrome: A consensus statement. J Clin Endocrinol Metab. 2003;88(12):5593-5602. doi: 10.1210/jc.2003-030871.
  • Kaltsas G, Chrisoulidou A, Piaditis G, et al. Current status and controversies in adrenal incidentalomas. Trends Endocrinol Metab. 2012;23(12):602-609. doi: 10.1016/j.tem.2012.09.001.
  • Tsagarakis S, Vassiliadi D, Thalassinos N. Endogenous sub-clinical hypercortisolism: Diagnostic uncertainties and clinical implications. J Endocrinol Invest. 2014;29(5):471-482. doi: 10.1007/bf03344133.
  • Elfenbein DM, Scarborough JE, Speicher PJ, et al. Comparison of laparoscopic versus open adrenalectomy: Results from american college of surgeons-national surgery quality improvement project. J Surg Res. 2013;184(1):216-220. doi: 10.1016/j.jss.2013.04.014.
  • Tsuiki M, Tanabe A, Takagi S, et al. Cardiovascular risks and their long-term clinical outcome in patients with subclini-cal Cushing's syndrome. Endocr J. 2008;55(4):737-745. doi: 10.1507/endocrj.K07E-177.
  • Akaza I, Yoshimoto T, Iwashima F, et al. Clinical outcome of subclinical Cushing's syndrome after surgical and conservative treatment. Hypertens Res. 2011;34(10):1111-1115. doi: 10.1038/hr.2011.90.
  • Iacobone M, Citton M, Viel G, et al. Adrenalectomy may improve cardiovascular and metabolic impairment and ameliorate quality of life in patients with adrenal incidentalomas and subclinical Cushing's syndrome. Surgery. 2012; 152(6):991-997. doi: 10.1016/j.surg.2012.08.054.
  • Terzolo M, Stigliano A, Chiodini I, et al. Ame position statement on adrenal incidentaloma. Eur J Endocrinol. 2011;164(6):851-870. doi: 10.1530/eje-10-1147.
  • Perysinakis I, Marakaki C, Avlonitis S, et al. Laparoscopic adrenalectomy in patients with subclinical Cushing's syndrome. Surg Endosc. 2013;27(6):2145-2148. doi: 10.1007/s00464-012-2730-5.
  • Morelli V, Reimondo G, Giordano R, et al. Long-term follow-up in adrenal incidentalomas: An italian multicenter study. J Clin Endocrinol Metab. 2014:jc.2013-3527. doi: 10.1210/jc.2013-3527.
  • Cawood TJ, Hunt PJ, O'shea D, et al. Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink? Eur J Endocrinol. 2009;161(4):513-527. doi: 10.1530/eje-09-0234.
  • Young WF. The incidentally discovered adrenal mass. N Engl J Med. 2007;356(6):601-610. doi: 10.1056/NEJMcp065470.
  • Bourdeau I. Aberrant membrane hormone receptors in incidentally discovered bilateral macronodular adrenal hyperpla-sia with subclinical Cushing's syndrome. J Clin Endocrinol Metab. 2001;86(11):5534-5540. doi: 10.1210/jc.86.11.5534.
  • Reznik Y, Lefebvre H, Rohmer V, et al. Aberrant adrenal sensitivity to multiple ligands in unilateral incidentaloma with sub-clinical autonomous cortisol hypersecretion: A prospective clinical study. Clin Endocrinol. 2004;61(3):311-319. doi: 10.1111/j.1365-2265.2004.02048.x.
  • Lacroix A, Baldacchino V, Bourdeau I, et al. Cushing's syndrome variants secondary to aberrant hormone receptors. Trends Endocrinol Metab. 2004;15(8):375-382. doi: 10.1016/s1043-2760(04)00188-2.
  • De Groot JWB, Links TP, Themmen APN, et al. Aberrant expression of multiple hormone receptors in acth-independent macronodular adrenal hyperplasia causing Cushing's syndrome. Eur J Endocrinol. 2010;163(2):293-299. doi: 10.1530/eje-10-0058.
  • Groussin L, Perlemoine K, Contesse V, et al. The ectopic expression of the gastric inhibitory polypeptide receptor is frequent in adrenocorticotropin-independent bilateral mac-ronodular adrenal hyperplasia, but rare in unilateral tumors. J Clin Endocrinol Metab. 2002;87(5):1980-1985. doi: 10.1210/jcem.87.5.8458.
  • Joubert M, Louiset E, Rego J-LD, et al. Aberrant adrenal sensitivity to vasopressin in adrenal tumours associated with subclinical or overt autonomous hypercortisolism: Is this explained by an overexpression of vasopressin receptors? Clin Endocrinol. 2008;68(5):692-699. doi: 10.1111/j.1365-2265.2007.03106.x.
  • Lacroix A. Ectopic and abnormal hormone receptors in adrenal a^hing's syndrome. Endocr Rev. 2001;22(1):75-110. doi: 10.1210/er.22.1.75.
  • Trejter M, Carraro G, Rucinski M, et al. Arginin-vasopressin regulates proliferative activity of the regenerating rat adrenal cortex. Int JMolMed. 2005. doi: 10.3892/ijmm.15.6.993.
  • Kero J, Poutanen M, Zhang F-P, et al. Elevated luteinizing hormone induces expression of its receptor and promotes steroidogenesis in the adrenal cortex. J Clin Invest. 2000; 105(5):633-641. doi: 10.1172/jci7716.
  • Lacroix A, Tremblay J, Rousseau G, et al. Propranolol therapy for ectopic р-adrenergic receptors in adrenal Cushing's syndrome. N Engl J Med. 1997;337(20):1429-1434. doi: 10.1056/nejm199711133372004.
  • Katz MS, Kelly TM, Dax EM, et al. Ectopic в-adrenergic receptors coupled to adenylate cyclase in human adreno-cortical carcinomas*. J Clin Endocrinol Metab. 1985;60(5): 900-909. doi: 10.1210/jcem-60-5-900.
  • Goyal A, Panchani R, Varma T, et al. Adrenal incidentaloma: A case of pheochromocytoma with sub-clinical Cushing's syndrome. Indian J Endocrinol Metab. 2013;17(7):246. doi: 10.4103/2230-8210.119587.
  • Kimura T, Usui T, Inamoto S, et al. Pheochromocytoma with subclinical Cushing's syndrome caused by corticomedullary mixed tumor of the adrenal gland. J Clin Endocrinol Metab. 2009;94(3):746-747. doi: 10.1210/jc.2008-2013.
  • Mazzuco TL, Thomas M, Martinie M, et al. Cellular and molecular abnormalities of a macronodular adrenal hyperplasia causing beta-blocker-sensitive Cushing's syndrome. Arq Bras EndocrinolMetabol. 2007;51(9):1452-1462. doi: 10.1590/s0004-27302007000900007.
  • Lacroix A, Hamet P, Boutin J-M. Leuprolide acetate therapy in luteinizing hormone-dependent Cushing's syndrome. N Engl J Med. 1999;341(21):1577-1581. doi: 10.1056/nejm199911183412104.

Views

Abstract - 942

PDF (Russian) - 1219


Copyright (c) 2015 Кузнецов Н.С., Тихонова О.В.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.